Coherus Oncology (CHRS) Intangibles (2014 - 2026)

Coherus Oncology has disclosed Intangibles across 13 years of filings, most recently posting $19.4 million for Q1 2026.

• Intangibles for Q1 2026 came in at $19.4 million, down 32.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.4 million (down 32.86% YoY), and the FY2025 annual result was $26.2 million, up 5.86% from the prior year.
• Intangibles came in at $19.4 million for Q1 2026 at Coherus Oncology, down from $26.2 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $28.9 million in Q3 2023 to a low of $1.6 million in Q3 2025.
• The 5-year median for Intangibles is $25.1 million (2024), against an average of $20.9 million.
• Across the five-year window, Intangibles soared 386.58% in 2023 and plunged 93.71% in 2025, its largest moves.
• Coherus Oncology's Intangibles stood at $5.9 million in 2022, then surged by 386.58% to $28.9 million in 2023, then fell by 14.11% to $24.8 million in 2024, then climbed by 5.86% to $26.2 million in 2025, then declined by 26.16% to $19.4 million in 2026.
• The last three Intangibles figures came in at $19.4 million (Q1 2026), $26.2 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.